Novo-backed startup touts a PhII win for atrial fibrillation program

Katherine Lewin

News Reporter

Denmark-based biotech Acesion Pharma is tackling atrial fibrillation (AF), the most common cardiac arrhythmia, with AP30663, its SK ion channel inhibitor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo-backed startup touts a PhII win for atrial fibrillation program

Katherine Lewin

News Reporter

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

A look at biotech's year of the megaround

Neumora's major depression drug flunks first of three Phase 3 trials

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Roche circles back to China biotech with $80M deal for lung cancer ADC

No­vo-backed start­up touts a PhII win for atri­al fib­ril­la­tion pro­gram

Katherine Lewin

News Reporter

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

A look at biotech's year of the megaround

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Novo-backed startup touts a PhII win for atrial fibrillation program

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Roche circles back to China biotech with $80M deal for lung cancer ADC